Defence Therapeutics closes $9.59M private placement

Executive Summary

• Defence Therapeutics Inc. closed a private placement of 17,445,455 units at $0.55 per unit, generating gross proceeds of $9,595,000.
• Each unit includes one common share and one common‑share purchase warrant (exercise price $0.65, exercisable for 24 months).
• Proceeds will be used to advance ADC and radiopharmaceutical programs, develop partnerships, and fund working capital.

Key Details

• Units sold: 17,445,455 units at $0.55 per unit.
• Gross proceeds: $9,595,000 (rounded to the nearest dollar).
• Unit composition: 1 common share + 1 warrant per unit.
• Warrant terms: Exercise price $0.65 per share; exercisable for 24 months from issuance; includes equity blocker (prevents holder exceeding 9.99% of outstanding shares).
• Prior term sheet: Binding term sheet with two institutional investors for $6 million under a sharing agreement dated March 6, 2026.
• Additional warrants issued under term sheet: 10,909,091 warrants, same exercise price and period as above.
• Corporate finance fee: 654,546 units transferred to the investors as a fee.
• Non‑refundable deposit: 118,182 units retained at the private placement price.
• Use of proceeds: Advance antibody‑drug conjugate (ADC) program, radiopharmaceutical program, develop partnerships, and general working capital.
• Finder’s fees: None paid.
• Resale restrictions: All securities subject to applicable Canadian securities law resale limits.

Notable Quotes

(No executive quotes were provided in the release.)